183 related articles for article (PubMed ID: 35105887)
1. The DNA methylome of cervical cells can predict the presence of ovarian cancer.
Barrett JE; Jones A; Evans I; Reisel D; Herzog C; Chindera K; Kristiansen M; Leavy OC; Manchanda R; Bjørge L; Zikan M; Cibula D; Widschwendter M
Nat Commun; 2022 Feb; 13(1):448. PubMed ID: 35105887
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic reprogramming of fallopian tube fimbriae in BRCA mutation carriers defines early ovarian cancer evolution.
Bartlett TE; Chindera K; McDermott J; Breeze CE; Cooke WR; Jones A; Reisel D; Karegodar ST; Arora R; Beck S; Menon U; Dubeau L; Widschwendter M
Nat Commun; 2016 May; 7():11620. PubMed ID: 27216078
[TBL] [Abstract][Full Text] [Related]
3. Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation.
Kotsopoulos J; Gronwald J; Karlan B; Rosen B; Huzarski T; Moller P; Lynch HT; Singer CF; Senter L; Neuhausen SL; Tung N; Eisen A; Foulkes WD; Ainsworth P; Sun P; Lubinski J; Narod SA;
Gynecol Oncol; 2018 Jul; 150(1):85-91. PubMed ID: 29793803
[TBL] [Abstract][Full Text] [Related]
4. Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers.
Staff S; Tolonen T; Laasanen SL; Mecklin JP; Isola J; Mäenpää J
Int J Gynecol Pathol; 2014 May; 33(3):309-16. PubMed ID: 24681744
[TBL] [Abstract][Full Text] [Related]
5. Prevalence, spectrum, and founder effect of BRCA1 and BRCA2 mutations in epithelial ovarian cancer from the Middle East.
Siraj AK; Bu R; Iqbal K; Siraj N; Al-Haqawi W; Al-Badawi IA; Parvathareddy SK; Masoodi T; Tulbah A; Al-Dayel F; Al-Kuraya KS
Hum Mutat; 2019 Jun; 40(6):729-733. PubMed ID: 30825404
[TBL] [Abstract][Full Text] [Related]
6. The WID-BC-index identifies women with primary poor prognostic breast cancer based on DNA methylation in cervical samples.
Barrett JE; Herzog C; Jones A; Leavy OC; Evans I; Knapp S; Reisel D; Nazarenko T; Kim YN; Franchi D; Ryan A; Franks J; Bjørge L; Zikan M; Cibula D; Harbeck N; Colombo N; Dudbridge F; Jones L; Sundström K; Dillner J; Rådestad AF; Gemzell-Danielsson K; Pashayan N; Widschwendter M
Nat Commun; 2022 Feb; 13(1):449. PubMed ID: 35105882
[TBL] [Abstract][Full Text] [Related]
7. Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma.
Soslow RA; Han G; Park KJ; Garg K; Olvera N; Spriggs DR; Kauff ND; Levine DA
Mod Pathol; 2012 Apr; 25(4):625-36. PubMed ID: 22193042
[TBL] [Abstract][Full Text] [Related]
8. BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers.
Maxwell KN; Wubbenhorst B; Wenz BM; De Sloover D; Pluta J; Emery L; Barrett A; Kraya AA; Anastopoulos IN; Yu S; Jiang Y; Chen H; Zhang NR; Hackman N; D'Andrea K; Daber R; Morrissette JJD; Mitra N; Feldman M; Domchek SM; Nathanson KL
Nat Commun; 2017 Aug; 8(1):319. PubMed ID: 28831036
[TBL] [Abstract][Full Text] [Related]
9. A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention.
Hanley GE; McAlpine JN; Miller D; Huntsman D; Schrader KA; Blake Gilks C; Mitchell G
BMC Cancer; 2018 Mar; 18(1):254. PubMed ID: 29506471
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of BRCA1 and BRCA2 pathogenic sequence variants in ovarian cancer patients in the Gulf region: the PREDICT study.
Azribi F; Abdou E; Dawoud E; Ashour M; Kamal A; Al Sayed M; Burney I
BMC Cancer; 2021 Dec; 21(1):1350. PubMed ID: 34930165
[TBL] [Abstract][Full Text] [Related]
11. Coming into focus: the nonovarian origins of ovarian cancer.
Dubeau L; Drapkin R
Ann Oncol; 2013 Nov; 24 Suppl 8(Suppl 8):viii28-viii35. PubMed ID: 24131966
[TBL] [Abstract][Full Text] [Related]
12. BRCA-associated ovarian cancer: from molecular genetics to risk management.
Girolimetti G; Perrone AM; Santini D; Barbieri E; Guerra F; Ferrari S; Zamagni C; De Iaco P; Gasparre G; Turchetti D
Biomed Res Int; 2014; 2014():787143. PubMed ID: 25136623
[TBL] [Abstract][Full Text] [Related]
13. Family history and BRCA1/BRCA2 status among Japanese ovarian cancer patients and occult cancer in a BRCA1 mutant case.
Hirasawa A; Masuda K; Akahane T; Ueki A; Yokota M; Tsuruta T; Nomura H; Kataoka F; Tominaga E; Banno K; Makita K; Susumu N; Sugano K; Kosaki K; Kameyama K; Aoki D
Jpn J Clin Oncol; 2014 Jan; 44(1):49-56. PubMed ID: 24218521
[TBL] [Abstract][Full Text] [Related]
14. A Dominantly Inherited 5' UTR Variant Causing Methylation-Associated Silencing of BRCA1 as a Cause of Breast and Ovarian Cancer.
Evans DGR; van Veen EM; Byers HJ; Wallace AJ; Ellingford JM; Beaman G; Santoyo-Lopez J; Aitman TJ; Eccles DM; Lalloo FI; Smith MJ; Newman WG
Am J Hum Genet; 2018 Aug; 103(2):213-220. PubMed ID: 30075112
[TBL] [Abstract][Full Text] [Related]
15. Genetic and epigenetic profiling of BRCA1/2 in ovarian tumors reveals additive diagnostic yield and evidence of a genomic BRCA1/2 DNA methylation signature.
Aref-Eshghi E; McGee JD; Pedro VP; Kerkhof J; Stuart A; Ainsworth PJ; Lin H; Volodarsky M; McLachlin CM; Sadikovic B
J Hum Genet; 2020 Oct; 65(10):865-873. PubMed ID: 32483276
[TBL] [Abstract][Full Text] [Related]
16. No Association of Early-Onset Breast or Ovarian Cancer with Early-Onset Cancer in Relatives in
Imbert-Bouteille M; Corsini C; Picot MC; Mizrahy L; Akouete S; Huguet H; Thomas F; Geneviève D; Taourel P; Ychou M; Galibert V; Rideau C; Baudry K; Kogut Kubiak T; Coupier I; Hobeika R; Macary Y; Toledano A; Solassol J; Maalouf A; Daures JP; Pujol P
Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356116
[TBL] [Abstract][Full Text] [Related]
17. Peripheral blood DNA methylation detected in the BRCA1 or BRCA2 promoter for sporadic ovarian cancer patients and controls.
Bosviel R; Michard E; Lavediaux G; Kwiatkowski F; Bignon YJ; Bernard-Gallon DJ
Clin Chim Acta; 2011 Jul; 412(15-16):1472-5. PubMed ID: 21557934
[TBL] [Abstract][Full Text] [Related]
18. Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883).
Hauke J; Hahnen E; Schneider S; Reuss A; Richters L; Kommoss S; Heimbach A; Marmé F; Schmidt S; Prieske K; Gevensleben H; Burges A; Borde J; De Gregorio N; Nürnberg P; El-Balat A; Thiele H; Hilpert F; Altmüller J; Meier W; Dietrich D; Kimmig R; Schoemig-Markiefka B; Kast K; Braicu E; Baumann K; Jackisch C; Park-Simon TW; Ernst C; Hanker L; Pfisterer J; Schnelzer A; du Bois A; Schmutzler RK; Harter P
J Med Genet; 2019 Sep; 56(9):574-580. PubMed ID: 30979843
[TBL] [Abstract][Full Text] [Related]
19. Germline mutations in Black patients with ovarian, fallopian tube and primary peritoneal carcinomas.
Somasegar S; Weiss AS; Norquist BM; Khasnavis N; Radke M; Manhardt E; Pennil C; Pennington KP; Eckert MA; Chryplewicz A; Lengyel E; Swisher EM
Gynecol Oncol; 2021 Oct; 163(1):130-133. PubMed ID: 34452747
[TBL] [Abstract][Full Text] [Related]
20. BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.
de Juan I; Palanca S; Domenech A; Feliubadaló L; Segura Á; Osorio A; Chirivella I; de la Hoya M; Sánchez AB; Infante M; Tena I; Díez O; Garcia-Casado Z; Vega A; Teulé À; Barroso A; Pérez P; Durán M; Carrasco E; Juan-Fita MJ; Murria R; Llop M; Barragan E; Izquierdo Á; Benítez J; Caldés T; Salas D; Bolufer P
Fam Cancer; 2015 Dec; 14(4):505-13. PubMed ID: 26026974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
